We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and ...

Instead of fixating on weight, McCann’s clients are encouraged to use other benchmarks, like waist measurements. Maintaining ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their ...

BMO chief strategist Brian Belski has launched a guided North American income portfolio, ...

Over-the-counter continuous glucose monitors empower consumers with valuable health insights without the need for a doctor’s ...

Using the CGM that Signos provided (Dexcom's G7 sensor) was less annoying and more informative than the finger prick method had been. But getting a CGM through Signos was not as simple—or ...

Its top products include the Dexcom G6 which provides real-time glucose monitoring, Dexcom G7 which is user-friendly and known for its accuracy, Dexcom Share System which allows remote monitoring ...

Dexcom has launched a generative AI platform ... designed as a more health and wellness-focused version of its mainstay G7 CGM—offering largely the same sensor capabilities, but without the ...

We continue to view Dexcom as a core holding and added to our position at a reset valuation. We believe the company’s upcoming G7 and Stelo glucose biosensor launches should drive further upside.

The company produces products like the Dexcom G6 and G7 CGM systems, Dexcom Share remote monitoring, and related software and mobile apps. Their core products include disposable glucose sensors ...

A pickleball player wears the Stelo over-the-counter CGM. [Image courtesy of Dexcom] Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its ...